Preparation method of ilaprazole crystal form A

By adding carbon dioxide to the alkali metal salt of ipprazole, the problems of large solvent consumption and instability in the prior art are solved, and the preparation of ipprazole crystal form A with high purity and good appearance is achieved, which is suitable for industrial production.

CN119060015APending Publication Date: 2024-12-03SHANGHAI HAOYUAN CHEMEXPRESS CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310649734.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-06-02
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The existing preparation methods for esprazole crystal form A have problems such as large solvent consumption, complex process, uneconomical industrial production, low production capacity and unstable under acidic conditions, resulting in difficulty in meeting the requirements of purity and appearance.

Method used

Carbon dioxide was added to the mixed solvent by adding carbon dioxide to the esprazole alkali metal salt, and the solid was precipitated and filtered and dried. By controlling the reaction conditions and the solvent ratio, high-purity esprazole crystal form A was obtained.

Benefits of technology

It achieves low impurity content, high purity and good product appearance, simplifies the process, is suitable for industrial production, and improves the stability of esprazole under acidic conditions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119060015A_ABST
    Figure CN119060015A_ABST
Patent Text Reader

Abstract

The invention relates to a preparation method of an ilaprazole crystal form A. The preparation method belongs to the technical field of medicines and chemistry, and the synthesis route is as follows: # imgabs0 # comprises the following steps: a) adding an ilaprazole alkali metal salt into a mixed solvent; b) adding carbon dioxide into the solution obtained in the step a), stirring to separate out a solid, and filtering after complete reaction; and c) drying to obtain the ilaprazole crystal form A, the ilaprazole alkali metal salt is preferably selected from ilaprazole lithium salt, ilaprazole sodium salt or ilaprazole potassium salt. The preparation method of the crystal form A has the advantages of simple process method, simplicity and convenience in operation, high purity and good appearance of the obtained product, and is suitable for pharmaceutical preparation development and industrial large-scale production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a method for preparing ilaprazole crystal form A, and belongs to the technical field of medicine and chemistry. Background Art

[0002] Ilaprazole, whose chemical name is 5-(1-hydrogen-pyrrol-1-yl)-2-[[(4-methoxy-3-methyl)-2-pyridinyl]-methyl]-sulfinyl-1-hydrogen-benzimidazole, has a chemical structure as shown in formula (1):

[0003]

[0004] Ilaprazole is a new type of irreversible proton pump inhibitor developed by Il-Yang Pharmaceutical Co., Ltd. of South Korea, which is suitable for duodenal ulcer and reflux esophagitis. Existing studies have shown that ilaprazole raw materials have polymorphic forms. The original research CN101687848B discloses A, B, E, F, and I crystal forms of ilaprazole shown in formula (1), among which crystal form A is the most thermodynamically stable among these crystal forms. Crystal form A has low solubility in liquid solutions, is non-hygroscopic, and has high bioavailability. At present, crystal form A is the best solid crystal form in solid preparations.

[0005] CN101687848B discloses a method for preparing ilaprazole crystal form A: 3% NH4OH / MeCN is placed in a flask, the temperature is adjusted to 5°C, ilaprazole is added, stirred for 1 hour, the filtrate is filtered off, and the filter cake is rinsed with 3% NH4OH / MeCN. The filter cake is placed in a flask, 0.5% NH4OH / EtOH is added, and the mixture is concentrated under reduced pressure at 20-25°C until there is no distillate. 0.5% NH4OH / EtOH and dichloromethane are then added to the flask. The resulting solution is concentrated under reduced pressure at 20-25°C. 0.5% NH4OH / EtOH is added, and the mixture is concentrated under reduced pressure at 20-25°C. 0.5% NH4OH / EtOH is added, the temperature is adjusted to 5°C, and stirred for 45 minutes. After filtering off the filtrate, it is rinsed with 0.5% NH4OH / EtOH, EtOH, and MTBE. The filter cake was dried for 2 hours and then vacuum dried for 92 hours at a maximum temperature of 53°C. The yield of racemic ilaprazole crystal form A was 85%, and the particle size was 206 μm. This preparation method requires a large amount of solvent, has a complex process, is not economical and environmentally friendly for industrial production, and has low production capacity.

[0006] WO2011071314A2 discloses another method for preparing ilaprazole crystal form A: ilaprazole sodium salt is added to ethanol, and 10% (w / w) ethanol acetic acid solution is slowly added to neutralize it. Then stir at room temperature for 2 hours. The obtained solid is filtered, washed with 50% (v / v) ethanol aqueous solution, and dried at 40°C for 12 hours to obtain white powder crystal form A with a yield of 86%. The inventors of the present application repeated Example 2 of WO2011071314A2 and found that ilaprazole sodium is unstable in the acetic acid free process, is easily degraded, and the appearance is difficult to meet the needs of formulation development; after in-depth exploration of the reasons, the inventors of the present application found that ilaprazole is unstable under acetic acid acid conditions, and its instability will also increase with the increase of acidity, so it is difficult to obtain a good purity ilaprazole finished product in the free process.

[0007] Therefore, there is an urgent need to develop a new method for preparing ilaprazole crystal form A. Summary of the invention

[0008] In order to solve the problems existing in the prior art, the object of the present invention is to provide a method for preparing ilaprazole crystal form A which has low impurity content, high purity, good product appearance and is easy for industrial production.

[0009] In order to achieve the above technical objectives, the present invention adopts the following technical solutions:

[0010] A method for preparing ilaprazole crystal form A, the synthesis route is as follows:

[0011]

[0012] The following steps are included:

[0013] a) adding ilaprazole alkali metal salt to a mixed solvent;

[0014] b) adding carbon dioxide to the solution obtained in step a), stirring to precipitate solid, and filtering after the reaction is complete;

[0015] c) drying to obtain ilaprazole crystal form A.

[0016] A method for preparing ilaprazole crystal form A, the synthesis route is as follows:

[0017]

[0018] The following steps are included:

[0019] a) adding ilaprazole alkali metal salt to a mixed solvent;

[0020] b) adding carbon dioxide to the solution obtained in step a), stirring to precipitate solid, and filtering after the reaction is complete;

[0021] c) drying to obtain ilaprazole crystal form A;

[0022] The alkali metal salt of ilaprazole is selected from ilaprazole lithium salt, ilaprazole sodium salt or ilaprazole potassium salt.

[0023] The present invention provides that the X-ray powder diffraction of ilaprazole crystalline form A has characteristic peaks at one, two or three of the diffraction angles 2θ values ​​of 7.9°, 8.5°, 13.2°, and 15.7°±0.2°; preferably, the X-ray powder diffraction of the ilaprazole crystalline form A has characteristic peaks at the diffraction angles 2θ values ​​of 7.9°, 8.5°, 13.2°, and 15.7°±0.2°.

[0024] In a preferred embodiment, the X-ray powder diffraction of the ilaprazole form A has characteristic peaks at diffraction angles 2θ of 7.9°, 8.5°, 13.2°, 15.7°, 15.9°, 16.6°, 17.8°, 19.7°, 20.1°, 20.9°, 23.0°, 23.5°, 24.1°, 24.6°, 25.1°, 25.7°, 26.1°, 26.8°, 29.2°, 29.6°, 30.3°, 35.7°, 36.4°, 37.8° and 38.8°±0.2°.

[0025] The ilaprazole crystal form A described in the present invention is defined as the ilaprazole crystal form A disclosed in patent CN101687848B, which has the following characteristics: Figure 1 The X-ray powder diffraction pattern is shown.

[0026] In a preferred embodiment, in step a), the mixed solvent is selected from a mixed solvent of water and an organic solvent, the mixed solvent is selected from water and an alcohol solvent, water and an ester solvent, water and a ketone solvent, water and an ether solvent or water and a halogenated alkane solvent; the mixed solvent is preferably water and an alcohol solvent, water and a ketone solvent or water and an ether solvent.

[0027] In a preferred embodiment, in step a), the mass volume ratio of the ilaprazole salt (eg, ilaprazole sodium) to the mixed solvent is 1:1 g / mL to 1:50 g / mL, preferably 1:10 g / mL to 1:30 g / mL.

[0028] In a preferred embodiment, in step a), the mixed solvent is selected from a mixed solvent of water and an organic solvent; the volume ratio of water to the organic solvent is selected from 1:1 to 1:50, more preferably 1:1.2 to 1:5, and most preferably 1:1.5 to 1:3.

[0029] In a preferred embodiment, in step a), the mixed solvent is selected from a mixed solvent of water and an organic solvent, the organic solvent is selected from an alcohol solvent, and the alcohol solvent is selected from methanol, ethanol, and isopropanol. The volume ratio of water to alcohol solvent (such as methanol, ethanol, isopropanol) is selected from 1:1 to 1:50, preferably 1:1.5 to 1:3; preferably, the volume ratio of water to methanol is selected from 1:1 to 1:50, further preferably 1:1.2 to 1:5, and most preferably 1:1.5 to 1:3.

[0030] In a preferred embodiment, in step a), the mixed solvent is selected from a mixed solvent of water and an organic solvent, the organic solvent is selected from an ester solvent, and the ester solvent is selected from ethyl acetate and isopropyl acetate. The volume ratio of water to ester solvent (such as ethyl acetate, isopropyl acetate) is selected from 1:1 to 1:50, preferably 1:1.5 to 1:3; preferably, the volume ratio of water to ethyl acetate is selected from 1:1 to 1:50, further preferably 1:1.2 to 1:5, and most preferably 1:1.5 to 1:3.

[0031] In a preferred embodiment, in step a), the mixed solvent is selected from a mixed solvent of water and an organic solvent, the organic solvent is selected from a ketone solvent, and the ketone solvent is selected from acetone. The volume ratio of water to alcohol solvent (such as acetone) is selected from 1:1 to 1:50, preferably 1:1.5 to 1:3; preferably, the volume ratio of water to acetone is selected from 1:1 to 1:50, further preferably 1:1.2 to 1:5, and most preferably 1:1.5 to 1:3.

[0032] In a preferred embodiment, in step a), the mixed solvent is selected from a mixed solvent of water and an organic solvent; the organic solvent is selected from an ether solvent, and the ether solvent is selected from isopropyl ether, methyl tert-butyl ether, and tetrahydrofuran. The volume ratio of water to alcohol solvent (such as isopropyl ether, methyl tert-butyl ether, and tetrahydrofuran) is selected from 1:1 to 1:50, preferably 1:1.5 to 1:3; preferably, the volume ratio of water to tetrahydrofuran is selected from 1:1 to 1:50, further preferably 1:1.2 to 1:5, and most preferably 1:1.5 to 1:3.

[0033] In a preferred embodiment, in step a), the mixed solvent is selected from a mixed solvent of water and an organic solvent, the organic solvent is selected from a halogenated alkane solvent, and the halogenated alkane solvent is selected from dichloromethane. The volume ratio of water to alcohol solvent (e.g. dichloromethane) is selected from 1:1 to 1:50, preferably 1:1.5 to 1:3; preferably, the volume ratio of water to dichloromethane is selected from 1:1 to 1:50, further preferably 1:1.2 to 1:5, and most preferably 1:1.5 to 1:3.

[0034] In a preferred embodiment, in step a), the mixed solvent is selected from a mixed solvent of water and methanol, water and ethanol, water and isopropanol, water and ethyl acetate, water and isopropyl acetate, water and acetone, water and isopropyl ether, water and methyl tert-butyl ether, water and tetrahydrofuran or water and dichloromethane, preferably a mixed solvent of water and methanol, water and ethanol, water and acetone or water and tetrahydrofuran; more preferably a mixed solvent of water and methanol.

[0035] As a further improvement of the embodiment of the present invention, the reaction temperature of adding carbon dioxide to the solution obtained in step a) in step b) is 10-100°C, preferably 10-30°C or 10-15°C or 15-20°C.

[0036] As a further improvement of the embodiment of the present invention, the temperature for stirring and precipitating the solid in step b) is -5 to 15°C, preferably 0 to 10°C.

[0037] As a further improvement of the embodiment of the present invention, the stirring time for stirring to precipitate solid in step b) is 1 to 12 hours, preferably 2 to 6 hours.

[0038] In step b), the carbon dioxide is added in the form of gas or dry ice.

[0039] In step b), after the addition of carbon dioxide, the reaction is complete and the pH value of the system is in the range of 7 to 8.

[0040] As a further improvement of the embodiment of the present invention, in step b), when the reaction is complete, the introduction of carbon dioxide can be stopped according to the pH value of the system being measured to be in the range of 7 to 8.

[0041] In step b), the carbon dioxide is added in the form of gas or dry ice, and the flow rate of the carbon dioxide gas is 0.1 to 20 L / h, preferably 0.1 to 10 L / h, and more preferably 0.1 to 5 L / h.

[0042] In step c), the drying conditions are selected from vacuum drying at 30-60° C., preferably 35-45° C.; the drying time is preferably 4-24 hours, preferably 6-12 hours.

[0043] In step c), the obtained ilaprazole crystal form A has the following Figure 1 The X-ray powder diffraction pattern shown has an HPLC purity of 99% or more, 99.5% or more.

[0044] Compared with the prior art, the present invention has the following beneficial effects:

[0045] The preparation method of ilaprazole crystal form A provided by the present invention solves the problems of using a large amount of solvent, complex process, instability during the strong acid freeing process, etc., greatly reduces the content of impurities, and the obtained ilaprazole crystal form A has high purity and good yield; and the process method is simple, easy to operate, high purity, and suitable for industrial production.

[0046] The present invention introduces carbon dioxide to form carbonic acid, and the pKa1 of carbonic acid is 6.37. The present invention particularly and unexpectedly finds that the introduction of carbon dioxide can completely liberate ilaprazole sodium into ilaprazole, and the acidity of carbonic acid is relatively weak, so the stability of ilaprazole in it is relatively good.

[0047] The preparation method provided in the present invention is different from all the preparation methods of the disclosed processes, has good reproducibility, is simple in process, and meets the application of subsequent preparations of ilaprazole; moreover, the reaction conditions of the preparation process are mild, no special requirements are placed on the equipment, environmental pollution is small, the product has good appearance, is a white or off-white solid, and the appearance of the crystal form A obtained by freeing with acetic acid is significantly improved. BRIEF DESCRIPTION OF THE DRAWINGS

[0048] Figure 1 is the X-ray powder diffraction (XPRD) pattern of ilaprazole Form A of the present invention;

[0049] Figure 2 The XPRD superposition spectrum of the ilaprazole crystal form A obtained in Comparative Example 1 and Examples 1, 2, 3, and 4 of the present invention;

[0050] Figure 3 The differential scanning calorimetry (DSC) spectrum of ilaprazole Form A described in Example 1 of the present invention;

[0051] Figure 4 This is the HPLC detection spectrum of ilaprazole Form A described in Example 1 of the present invention;

[0052] Figure 5 This is the HPLC detection spectrum of ilaprazole Form A obtained in Comparative Example 1. DETAILED DESCRIPTION

[0053] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention.

[0054] Comparative Example 1

[0055] 5 g of ilaprazole sodium salt (purity 99.88%) was placed in a three-necked flask and added to 100 mL of ethanol. 8.1 g of 10% (w / w) ethanol acetic acid solution was slowly added to the system at a temperature below 15°C. Ethanol acetic acid was added to the solution to precipitate a light pink solid. Stirring was continued at 0-10°C for 6 hours, filtered, washed with 20 mL of 50% (v / v) ethanol aqueous solution, and dried at 35-40°C for 12 hours to obtain 3.86 g of purple powder with a yield of 81.8%. The product was ilaprazole Form A. The X-ray powder diffraction (XPRD) spectrum was as follows: Figure 2 XRPD spectrum shown. Purity 99.77%, HPLC spectrum as shown Figure 5 Under stirring at 0-10°C, the color of the precipitated solid and the purity of the suspension sample were recorded every 2 hours. The results are summarized in Table 1.

[0056] Example 1

[0057] 10 g of ilaprazole sodium salt (purity 99.88%) was added to a three-necked flask, and 100 mL of methanol and 60 mL of water were added. The temperature was controlled below 15° C. and carbon dioxide gas was introduced into the system. Carbon dioxide gas was introduced into the solution, and white solid precipitated. Carbon dioxide gas was introduced until the pH of the system was 7-8, and the introduction of carbon dioxide was stopped until no solid precipitated. The temperature was controlled to 0-10° C. and stirring was continued for 4 hours. The mixture was filtered, rinsed with methanol aqueous solution, and vacuum dried at 35-40° C. for 12 hours to obtain 8.07 g of white powder with a yield of 85.5%. The product was ilaprazole crystal form A. The XRPD spectrum is shown as follows: Figure 2 As shown, the DSC spectrum is Figure 3 As shown. Purity 99.94%, HPLC spectrum and Figure 4 shown.

[0058] Example 2

[0059] 10 g of ilaprazole sodium salt (purity 99.88%) was added to a three-necked flask, and 100 mL of ethanol and 60 mL of water were added. Carbon dioxide gas was introduced into the system at a temperature below 15° C. When carbon dioxide gas was introduced into the solution, white solid precipitated. Carbon dioxide gas was introduced until the pH of the system was 7-8, and the introduction of carbon dioxide was stopped until no solid precipitated. The temperature was controlled to 0-10° C. and stirring was continued for 3 hours. The mixture was filtered, rinsed with ethanol aqueous solution, and vacuum dried at 35-40° C. for 8 hours to obtain 8.14 g of white powder with a yield of 86.3%. The product was ilaprazole crystal form A with a purity of 99.97%. The XRPD spectrum was as follows: Figure 2 As shown, the XRPD pattern is Figure 1 The DSC spectrum is consistent with Figure 3 Consistent.

[0060] Example 3

[0061] 10 g of ilaprazole sodium salt (purity 99.88%) was added to a three-necked flask, and 100 mL of methanol and 60 mL of water were added. The temperature was controlled below 15° C., and carbon dioxide gas was added to the system. When carbon dioxide gas was introduced into the solution, white solid precipitated. Carbon dioxide gas was introduced until the pH of the system was 7-8, and the introduction of carbon dioxide was stopped until no solid precipitated. The temperature was controlled to 0-10° C. and stirring was continued for 4 hours. The mixture was filtered, rinsed with methanol aqueous solution, and vacuum dried at 35-40° C. for 12 hours to obtain 7.99 g of white powder with a yield of 84.7%. The product was ilaprazole crystal form A with a purity of 99.96%. The XRPD spectrum was as follows: Figure 2 As shown, the XRPD pattern is Figure 1 The DSC spectrum is consistent with Figure 3 Consistent.

[0062] Example 4

[0063] 10 g of sodium ilaprazole (purity 99.88%) was added to a three-necked flask, and 100 mL of methanol and 100 mL of water were added. Carbon dioxide gas was introduced into the system at a temperature of 15°C to 20°C. Carbon dioxide gas was introduced into the solution, and a white solid was precipitated. The mixture was then stirred at 0 to 10°C for 6 hours. The color of the precipitated solid and the purity of the suspension sample were recorded every 2 hours. The results are summarized in Table 1 below. Carbon dioxide gas was introduced until the pH of the system was about 7 to 8, and the introduction of carbon dioxide was stopped until no solid precipitated. The mixture was then cooled to 0 to 10°C under stirring, filtered, rinsed with methanol aqueous solution, and vacuum dried at 35 to 40°C for 6 hours to obtain 8.03 g of white powder with a yield of 85.12%. The product was ilaprazole crystal form A with a purity of 99.74%. The XRPD spectrum was as follows: Figure 2 As shown, the XRPD pattern is Figure 1 The DSC spectrum is consistent with Figure 3 Consistent.

[0064] Table 1 Summary of the comparison of appearance and purity of acetic acid and carbon dioxide

[0065]

[0066] Among them, impurity 1 and impurity 3 are controlled as unknown impurities, and the structures of impurity 2 and impurity 4 are as follows:

[0067]

[0068] According to the test results in Table 1, the test results show that the Form A crystal preparation process with carbon dioxide introduced has a better appearance of the Form A crystal, which is white or off-white solid; the acetic acid process control produces two known impurities, RRT0.88 and RRT1.35, in 2 hours, and the color continues to deepen over time, and the colors are light pink, lavender, and purple at 2 hours, 4 hours, and 6 hours, respectively. In the comparative test, the impurity content of the Form A crystal preparation process of carbon dioxide is better than that of the Form A crystal preparation process of acetic acid. In particular, the two known impurities, impurity 2 and impurity 4, can be better controlled in the free process by using carbonic acid to free (Form A crystal preparation process of carbon dioxide), which has obvious technical advantages over acetic acid.

Claims

1. A method for preparing ilaprazole crystal form A, the synthetic route is as follows: M = alkali metal, preferably Li, Na or K The following steps are included: a) adding ilaprazole alkali metal salt to a mixed solvent; b) adding carbon dioxide to the solution obtained in step a), stirring to precipitate solid, and filtering after the reaction is complete; c) drying to obtain ilaprazole crystal form A; The ilaprazole alkali metal salt is preferably ilaprazole lithium salt, ilaprazole sodium salt or ilaprazole potassium salt.

2. The preparation method according to claim 1, characterized in that: The X-ray powder diffraction of the ilaprazole crystal form A has characteristic peaks at diffraction angles 2θ of 7.9°, 8.5°, 13.2°, and 15.7°±0.2°; Preferably, the X-ray powder diffraction of the ilaprazole crystalline form A has characteristic peaks at diffraction angles 2θ of 7.9°, 8.5°, 13.2°, 15.7°, 15.9°, 16.6°, 17.8°, 19.7°, 20.1°, 20.9°, 23.0°, 23.5°, 24.1°, 24.6°, 25.1°, 25.7°, 26.1°, 26.8°, 29.2°, 29.6°, 30.3°, 35.7°, 36.4°, 37.8° and 38.8°±0.2°; Alternatively, the ilaprazole Form A preferably has an X-ray powder diffraction pattern as shown in FIG1 .

3. The preparation method according to claim 1 or 2, characterized in that: In the step a), the mixed solvent is selected from a mixed solvent of water and an organic solvent, and the mixed solvent is selected from water and an alcohol solvent, water and an ester solvent, water and a ketone solvent, water and an ether solvent or water and a halogenated alkane solvent; the mixed solvent is preferably water and an alcohol solvent, water and a ketone solvent or water and an ether solvent; Preferably, in step a), the mixed solvent is selected from a mixed solvent of water and an organic solvent; the volume ratio of water to the organic solvent is selected from 1:1 to 1:50, preferably 1:1.5 to 1:3; Preferably, in step a), the mass volume ratio of the ilaprazole salt to the mixed solvent is 1:1 g / mL to 1:50 g / mL, more preferably 1:10 g / mL to 1:30 g / mL; the ilaprazole salt is preferably ilaprazole sodium salt.

4. The preparation method according to claim 1 or 2, characterized in that: In step a), the mixed solvent is selected from a mixed solvent of water and an organic solvent, the organic solvent is selected from an alcohol solvent, and the alcohol solvent is selected from methanol, ethanol, and isopropanol; preferably, the volume ratio of water to methanol is selected from 1:1 to 1:50, more preferably 1:1.2 to 1:5, and even more preferably 1:1.5 to 1:3; Preferably, in step a), the mixed solvent is selected from a mixed solvent of water and an organic solvent, the organic solvent is selected from an ester solvent, and the ester solvent is selected from ethyl acetate and isopropyl acetate; preferably, the volume ratio of water to ethyl acetate is selected from 1:1 to 1:50, more preferably 1:1.2 to 1:5, and even more preferably 1:1.5 to 1:3; Preferably, in step a), the mixed solvent is selected from a mixed solvent of water and an organic solvent, the organic solvent is selected from a ketone solvent, and the ketone solvent is selected from acetone; preferably, the volume ratio of water to acetone is selected from 1:1 to 1:50, more preferably 1:1.2 to 1:5, and even more preferably 1:1.5 to 1:3; Preferably, in step a), the mixed solvent is selected from a mixed solvent of water and an organic solvent, the organic solvent is selected from an ether solvent, the ether solvent is selected from isopropyl ether, methyl tert-butyl ether, and tetrahydrofuran; preferably, the volume ratio of water to tetrahydrofuran is selected from 1:1 to 1:50, more preferably 1:1.2 to 1:5, and even more preferably 1:1.5 to 1:3; Preferably, in step a), the mixed solvent is selected from a mixed solvent of water and an organic solvent; the organic solvent is selected from a halogenated alkane solvent, and the halogenated alkane solvent is selected from dichloromethane; preferably, the volume ratio of water to dichloromethane is selected from 1:1 to 1:50, more preferably 1:1.2 to 1:5, and even more preferably 1:1.5 to 1:

3.

5. The preparation method according to claim 1 or 2, characterized in that In step a), the mixed solvent is selected from a mixed solvent of water and methanol, water and ethanol, water and isopropanol, water and ethyl acetate, water and isopropyl acetate, water and acetone, water and isopropyl ether, water and methyl tert-butyl ether, water and tetrahydrofuran or water and dichloromethane, preferably a mixed solvent of water and methanol, water and ethanol, water and acetone or water and tetrahydrofuran; more preferably a mixed solvent of water and methanol.

6. The preparation method according to claim 1 or 2, characterized in that: The reaction temperature of adding carbon dioxide to the solution obtained in step a) in step b) is 10-100°C, preferably 10-30°C, 10-15°C or 15-20°C; Preferably, the temperature for stirring and precipitating the solid in step b) is -5 to 15°C, preferably 0 to 10°C; Preferably, the stirring time for stirring to precipitate solid in step b) is 1 to 12 hours, preferably 2 to 6 hours.

7. The preparation method according to claim 1 or 2, characterized in that: In step b), the carbon dioxide is added in the form of gas or dry ice.

8. The preparation method according to claim 1 or 2, characterized in that: In step b), after the addition of carbon dioxide, the reaction is complete and the pH value of the system is in the range of 7 to 8; Or preferably, in step b), when the reaction is complete, the introduction of carbon dioxide can be stopped according to the pH value of the system being measured to be in the range of 7 to 8.

9. The preparation method according to claim 1 or 2, characterized in that: In step b), the carbon dioxide is added in the form of gas or dry ice, and the flow rate of the carbon dioxide gas is 0.1 to 20 L / h, preferably 0.1 to 10 L / h, and more preferably 0.1 to 5 L / h.

10. The preparation method according to claim 1 or 2, characterized in that: In step c), the drying conditions are selected from vacuum drying at 30-60°C, preferably 35-45°C; the drying time is preferably 4-24 hours, preferably 6-12 hours; In step c), the obtained ilaprazole crystal form A has an X-ray powder diffraction pattern as shown in FIG. 1 , and an HPLC purity of 99.5% or higher.